Antibiotics With Bacteria-Specific, Rather Than Site-Specific, Indication Headed To US FDA

 
• By Joseph Haas

Entasis is seeking a pathogen-specific approval for its antibiotic/beta lactamase inhibitor candidate rather than an indication specific the site of an infection. Achaogen’s earlier failure to do the same may have helped set a path.

PS2110_Acinetobacter Baumannii_1200-BDGNT6 (Alamy)
Up close, Acinetobacter Baumannii may not look it much, but developing treatments has taken a lot of industry-regulator collaboration. • Source: Alamy

More from Review Pathways

More from Pathways & Standards